End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.3 MXN | +1.14% | +7.17% | +5.22% |
Apr. 24 | Transcript : ALPEK, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 24, 2024 | |
Apr. 23 | ALPEK, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.4 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.22% | 1.65B | B+ | ||
+21.31% | 5.58B | C | ||
-8.99% | 4.55B | C- | ||
-2.51% | 3.6B | C | ||
-0.50% | 2.11B | - | - | |
-13.78% | 1.28B | B | ||
-9.05% | 978M | - | D+ | |
-7.02% | 927M | - | ||
-5.37% | 588M | - | - | |
-25.35% | 453M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALPEK A Stock
- Ratings ALPEK, S.A.B. de C.V.